Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21104354 | 0.86 | HDAC3 (0.44) | FAAHMEN1MAPK1KMT2ACES2 | |
| SCHEMBL7180177 | 0.78 | HSP90AA1 (0.54) | FAAHMEN1MAPK1KMT2AHSP90AA1 | |
| SCHEMBL2807682 | 0.78 | HSP90AA1 (0.54) | FAAHMEN1MAPK1KMT2AHSP90AA1 | |
| SCHEMBL2810388 | 0.78 | EPHX2 (0.62) | FAAHMEN1MAPK1KMT2AHSP90AA1 | |
| SCHEMBL13366726 | 0.77 | GRIA1 (0.38) | MEN1MAPK1KMT2ACA1CA2 | |
| SCHEMBL23792182 | 0.76 | TERT (0.35) | CA1CA2 | |
| SCHEMBL11649466 | 0.76 | HSP90AA1 (0.57) | FAAHMEN1MAPK1KMT2AHSP90AA1 | |
| SCHEMBL21060856 | 0.76 | HSP90AA1 (0.57) | FAAHMEN1MAPK1KMT2AHSP90AA1 | |
| SCHEMBL7184916 | 0.76 | HSP90AA1 (0.57) | FAAHMEN1MAPK1KMT2AHSP90AA1 | |
| SCHEMBL7185340 | 0.76 | HSP90AA1 (0.57) | FAAHMEN1MAPK1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | FAAH 1937/4885MEN1 1035/4885MAPK1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.